You are given a text that consists of multiple sentences. Your task is to perform abstractive summarization on this text. Use your understanding of the content to express the main ideas and crucial details in a shorter, coherent, and natural sounding text.

DUBLIN, June 19, 2020 /PRNewswire/ -- The "Global Spinal Muscular Atrophy Market [(By Drugs - Spinraza, Zolgensma, Risdiplam & Reldesemtiv; By Region - North America (The US), Europe & Asia Pacific)] Market Outlook 2027" report has been added to ResearchAndMarkets.com's offering. The Global Spinal Muscular Atrophy (SMA) market is estimated to be valued at US$ 2.8 billion in the year 2027, growing at a CAGR of 12.5% in the period 2020 to 2027. Growth of the market is driven by rising incidences of SMA, technological advancements, government impetus, growing consumer awareness and a surge in R&D activities. SMA is a rare genetic disorder that affects the part of the central nervous system which controls voluntary muscle movements. It is one of the most common debilitating genetic disorders and a leading genetic cause of death among infants. It affects approximately one in 10,000 live births globally. FDA Approval of Zolgensma, the first gene therapy approved to treat children less than two years of age with spinal muscular atrophy (SMA), has become a milestone in the treatment of patients with SMA. It has emerged as a potential game-changer for SMA treatment. Furthermore, there are various other emerging ongoing clinical trials currently in the process of evaluating its efficacy of either SMN-dependent or SMN-independent approaches. This report provides detailed analysis of the global SMA market from qualitative and quantitative outlooks during the forecast period across various therapeutic segments. It also provides coverage on market dynamics with potential impact on the market during the forecast period and an in-depth analysis of the leading companies operating in the market. The report provides revenue forecasts for global, regional and country levels. It also provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. For the purpose of research, the global Spinal Muscular Atrophy has been segmented on the basis of therapeutics and regions. Key questions answered in the report The historical market size of the SMA market from 2016 to 2019 in US$ Millions and market volume in Millions. Projected market growth in the forecasted period 2020 to 2025 with estimated revenue for each year in US$ Millions. Revenue forecasts of major drugs in the period 2020 to 2027 in US$ Millions. Regional and country analysis of SMA market is provided for the period 2016 to 2027 in US$ Millions. Market drivers, restraints and industry trends that have an impact on revenue. Profiling of major companies with detailed analysis of drugs approved and in the pipeline. Key Topics Covered: 1. Executive Summary 2. Research Methodology 3. Spinal Muscular Atrophy3.1 Overview3.1.1 Causes3.1.2 Symptoms of SMA3.1.3 Types of Diseases3.2 Diagnosis & Treatment3.2.1 Diagnosis 3.2.2 Treatment3.2.2.1 Gene Therapy3.2.2.2 Medications 3.2.2.3 Existing Treatment Paradigm 4. Market Analysis4.1 Market Sizing (Actual & Forecasted)4.1.1 Market Sizing by Value (Actual & Forecasted)4.1.2 Market Sizing by Volume (Actual & Forecasted)4.2 Market Share Analysis4.2.1 Market Share by Disease Type4.2.2 Market Share by Route of Administration4.2.3 Market Share by Region4.2.4 Market Share by Patient Age-Group 5. Market Segmentation by Drugs5.1 Spinraza5.1.1 Overview5.1.2 Market Sizing (Actual & Forecasted)5.2 Zolgensma (AVXS - 101)5.2.1 Overview5.2.2 Market Sizing (Actual & Forecasted)5.2.3 Market Share by Disease Type5.2.4 Market Share by Region5.3 Risdiplam5.3.1 Overview5.3.2 Market Sizing (Actual & Forecasted)5.3.3 Market Share by Disease Type5.3.4 Market Share by Region5.4 Reldesemtiv5.4.1 Overview5.4.2 Market Sizing (Actual & Forecasted) 6. Regional Analysis6.1 North America - The US6.2 Europe6.3 Asia Pacific 7. Market Dynamics7.1 Industry Trends & Developments7.1.1 FDA Approval of Innovative Gene Therapy7.1.2 Mergers & Acquisitions7.1.3 Advent of Oral mRNA Splicer for Treatment7.1.4 Use of MRI as a Diagnostic Technique7.2 Growth Drivers7.2.1 Rising Incidences of SMA7.2.2 Technological Advancements7.2.3 Government Impetus7.2.4 Growing Consumer Awareness7.2.5 Surge in R&D Activities7.3 Challenges7.3.1 High Cost of Therapy7.3.2 Low Adoption of Treatment7.3.3 Unfavorable Reimbursement Policies 8. Competitive Landscape8.1 Financial Analysis8.2 Products Landscape 9. Company Profiles9.1 Biogen Inc.9.2 Cytokinetics, Inc.9.3 AveXis, Inc. (Novartis AG)9.4 F. Hoffmann-La Roche AG9.5 Ionis Pharmaceuticals, Inc. For more information about this report visit https://www.researchandmarkets.com/r/pmnjx4 About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. Media Contact: Research and Markets Laura Wood, Senior Manager [emailprotected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 SOURCE Research and Markets Related Links http://www.researchandmarkets.com

Answer: Global Spinal Muscular Atrophy Market Outlook to 2027 - Advent of Oral mRNA Splicer for Treatment